Patents by Inventor Abdelkrim Alloui

Abdelkrim Alloui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of riluzole for treating or preventing the adverse effects of antineoplastic agents
    Patent number: 9511045
    Abstract: This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: December 6, 2016
    Assignee: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Jérôme Busserolles, Abdelkrim Alloui, Michel Lazdunski, Alain Eschalier
  • Use of K2P potassium channel activators as antalgics
    Patent number: 9448242
    Abstract: The present invention relates to treating and preventing pain. More particularly the present invention demonstrates the involvement of K2P potassium channels in the antalgic effect of morphine. The present invention therefore provides a screening method for identifying antalgics.
    Type: Grant
    Filed: September 21, 2010
    Date of Patent: September 20, 2016
    Assignee: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Alain Eschalier, Jéröme Busserolles, Abdelkrim Alloui, Michel Lazdunski
  • USE OF RILUZOLE FOR TREATING OR PREVENTING THE ADVERSE EFFECTS OF ANTINEOPLASTIC AGENTS
    Publication number: 20130064775
    Abstract: This invention relates to riluzole for use in the treatment or prevention of adverse effects associated with the administration of anticancer agents having neurotoxic effects, such as, for example, platinum salts, taxanes and periwinkle alkaloids.
    Type: Application
    Filed: March 2, 2011
    Publication date: March 14, 2013
    Applicant: UNIVERSITE D'AUVERGNE CLERMONT I
    Inventors: Jérôme Busserolles, Abdelkrim Alloui, Michel Lazdunski, Alain Eschalier
  • Use of K2P Potassium Channel Activators as Antalgics
    Publication number: 20120260354
    Abstract: The present invention relates to treating and preventing pain. More particularly the present invention demonstrates the involvement of K2P potassium channels in the antalgic effect of morphine. The present invention therefore provides a screening method for identifying antalgics.
    Type: Application
    Filed: September 21, 2010
    Publication date: October 11, 2012
    Inventors: Alain Eschalier, Jéröme Busserolles, Abdelkrim Alloui, Michel Lazdunski